Adenoviral and recombinant IGFBP3 inhibited vascularization and angiogenesis-stimulating activities of HNSCC by suppressing the production of vascular endothelial growth factor (VEGF) [15]. The gene discussed is IGFBP3; the disease is head and neck squamous cell carcinoma.